In an invited presentation today before the annual meeting of the American Academy of Neurology, Knopp Neurosciences Inc. ("Knopp") described further encouraging trends observed in a previously reported Phase 2 study of KNS-760704 (dexpramipexole) in ALS. Knopp reported that post hoc analyses...